Tirzepatide Injections
Compounded Tirzepatide is a once-weekly injection, personalized with either B6, Glycine, or B12, depending on the patient's needs. It is specifically formulated for patients who do not tolerate the standard formulation or for those who need a customized treatment approach. All medications come from licensed USA partner pharmacies and are compounded in compliance with section 503A of the Federal Food, Drug, and Cosmetic Act. They are dispensed by our partner pharmacies solely pursuant to a valid patient-specific prescription from a licensed healthcare provider.
The addition of B6, Glycine, or B12 is intended to support patients experiencing issues such as neuropathy, muscle loss, or fatigue, and are compounded exclusively to meet the clinical needs of patients when commercially available alternatives are not appropriate for the individual.
If Prescribed, Product Purchase Includes:
– Medication
– Medical provider consultation
– Syringes
– Alcohol Pads
– Program guide
– Administration video
Administration and Frequency:
- Subcutaneous (SQ) Injection
- Requires step-up dosing:
Weeks 1-4: One 10mg Vial - Inject 2.5mg once a week
Weeks 5-8: One 20mg Vial - Inject 5mg once a week
Weeks 9-12: One 30mg Vial - Inject 7.5mg once a week
*Weeks 13-16+: One 40mg Vial - Inject 10mg once a week.
*Weeks 17-20+: One 50mg Vial - Inject 12.5mg once a week.
Weeks 21-24+: One 60mg Vial - Inject 15mg once a week
*You can stay at this dose if the product is still working well and you are losing weight. If you have plateaued, speak with your medical provider about increasing your dose.
Disclaimer: The FDA does not approve nor review compounded products for safety, effectiveness, or quality. They are not the same as Ozempic®, Wegovy®, Zepbound® or Mounjaro®, which are FDA-approved. Compounded versions may not meet the standards that brand names have met. Data from clinical trials for FDA approved medications should not be utilized to make decisions related to compounded medications.
FDA-approved medications such as Saxenda®, Victoza®, Wegovy®, and Ozempic® are trademarks of Novo Nordisk™, while Mounjaro™ is a product of Eli Lilly and Company™. The HCG Institute is not associated with or endorsed by these companies or their products. We do not supply these medications. If you have questions or concerns about your health or are interested in these products, please consult a healthcare professional.
The HCG Institute is a patient management platform that partners with independent licensed physician networks to deliver medical services through our infrastructure. All medications come from licensed USA partner pharmacies and are compounded in compliance with section 503A of the Federal Food, Drug, and Cosmetic Act. They are dispensed by our partner pharmacies solely pursuant to a valid patient-specific prescription from a licensed healthcare provider.
Medication will only be prescribed by a licensed clinician if deemed medically appropriate after a thorough consultation. Providers may prescribe compounded medications as needed to meet patient requirements. Results are not guaranteed and may vary based on the individual as part of a personalized weight loss program. This site is an advertisement for telehealth services, and any treatment or prescription is at the sole discretion of the prescribing provider.
Actual medication form and appearance may differ from what is shown. Information on this website is for educational purposes only and does not replace professional medical advice, diagnosis, or treatment. If you have health-related questions or concerns, please consult your doctor.
